SEC Form 4 · accession 0001171843-16-008389
Sucampo Pharmaceuticals, Inc. · SCMP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter Greenleaf
Officer — Chief Executive Officer
Period of report
Mar 2, 2016
Accepted (ET)
Mar 4, 2016 · 5:56 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001365216
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, Class A (ESPP)F1,F2 | Dec 31, 2015 | A | 476 | $14.70 | A | 476 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F3 | $13.80 | Mar 2, 2016 | A | 420,000 | A | — | Mar 2, 2026 | Class A Common Stock | 420,000 | 1,630,000 | D |
Explanation of responses
- F1The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's Employee Stock Purchase Plan (ESPP) for the period October 1, 2015 through December 31, 2015. This transaction is exempt under Rule 16(b)-3(c).
- F2In accordance with the ESPP, these shares were purchased at 85% of the closing price of the issuer's common stock on December 31, 2015.
- F3The option vests in 4 equal annual installments beginning on March 2, 2017.